Abstract: Background and objectives: due to the neurotoxic effect caused by high levels of cortisol, 13 studies suggest that stress and certain psychiatric disorders, such as mood disorders, have 14 influences under the hippocampus, causing a decrease in volume and consequent memory changes.
Introduction

34
As mood disorders, we have according with the Diagnostic and Statistical Manual of Mental Major Depressive Disorder (MDD) is the most prevalent mood disorder and is the first leading cause of living with disability for years [1, 2] . Pathologically, MDD is responsible for cognitive and emotional changes, including the neurovegetative system and also in the regulation of mood, anxiety and memory. The most recent studies have presented some histopathological alterations in the neural the patients' response to anti-depressive treatment or consequent recovery from mood disorders. The 79 regulation of mood and behavior is another hippocampus role, but the involvement of progenitor 80 cells on it is more complex than we observe in memory and learning, once anti-depressants intake 81 suggests stimulation at neurogenesis [6] . By the other side when we have a disruption in any glial 82 cell function there is a deregulation in brain energy supplies and more chances for developing 83 neuropsychiatric disorders [3] .
84
Evidences have supported the idea that acute exposure to stress decreases proliferation of NSCs 85 in the dentate gyrus (DG), and when the exposure is chronic there is also suppress at neuronal 86 differentiation and/or cell survival. Another suggestion points that the stress effects would not only 87 affect adults' hippocampal neurogenesis, but could also impacts the fetus during prenatal when the 88 mother is exposed to stress, damaging the brain development and bringing long-life consequences
89
[6].
90
Neuromorphometric abnormalities are observed in individuals with early-onset mood disorders 91 that appear anatomically related structures within the temporal lobe, thalamus, striatum and 92 posterior cingulate [2] . In depressed subjects the time spent without pharmacological treatment 93 seems to decrease the hippocampus volume, the same way that evidences show a decrease in the amygdala volume in patients with BD. Both represent the way that the limbic system can be related with neurotrophic effects in subjects with mood disorders [2, 5] and the fruits of these alterations on
The main objective of this study was study the relation between hippocampal volume changes with patients under some kind of treatment, pharmacological or non-pharmacological, were 
Type of Intervention/Exposition
123
The expositions considered were acute and chronic episodes in mood disorders 124
Type of Outcome
125
The outcome was the measurement of hippocampal volume in patients' brains using Magnetic
126
Resonance Imaging (MRI).
127
Review Criteria
128
The search in the databases was performed independently by two authors who selected articles 129 for analysis. Any disagreement was solved by consensus.
Search Strategy
The search terminology included the terms "Hippocampus", "Mood Disorders" and "MRI". At consensus were resolved by consensus.
The quality of each individual article included in this word was assessed by modified Cochrane review criteria [8] for clinical trials and the Agency for Healthcare Research and Quality (AHRQ) 145 criteria for observational studies [9] . Only studies scoring at least 50 points in one of both scales were included on the analysis. Methodological assessment criteria are described in Table 1 and Table 2 . Table 1 . Methodical assessment for observational study.
148
Criteria Weighted
Score
Points
Elbjeijjani et al [17] .
Phillips et al [18] .
Wise et al [19] .
Sivakumar et al [20] .
Redlich et al. [21] Sämann et al [22] . 
Search Methods for study identification
The data was extracted by two independent authors using a standard form. 
161
From clinical trials, 2 met the established inclusion criteria [10, 11] . The study of Miskowiak et al.
162
[10] was excluded because intervention involved erythropoietin administration in patients. The result
163
of the methodological quality assessment of clinical trials is illustrated in Table 2 . The quality 164 assessment criteria ranged was 52 points for evidence synthesis.
165
From observational studies, 12 met the established inclusion criteria [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Five of them were excluded from qualitative synthesis: Philips et al [12] analyzed gene polymorphism related to Table 3 . The quality assessment criteria ranged from 71 to 88 points for evidence synthesis. 
221
Sämann et al [22] compared 167 patients with depressive episodes, hospitalized over 3 years to 222 92 healthy controls. Symptoms were evaluated using a 21 item HRSD at baseline and within 5 weeks.
223
Significant reduction was detected in left hippocampus, especially in recurrent unipolar patients.
224
Besides, differences in response to treatment was significantly associated with left hippocampus. 
